{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:27:52Z","timestamp":1780648072846,"version":"3.54.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Research Training Scholarship, Australia Government"},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We aimed to identify motivators for people who inject drugs to pursue treatment for hepatitis C virus (HCV) infection and uncover opportunities that could make treatment more appealing.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Between November 2023 and January 2024, we conducted semi-structured interviews with 15 HCV RNA-positive individuals with a history of injecting drug use and self-reported as either untreated or treated but delayed treatment for more than 6 months. Thematic and framework data analysis was employed and interpreted using the Capability, Opportunity and Motivation (COM-B) framework of behaviour change.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The findings suggest that a combination of stability through secure housing, mental readiness and overcoming drug dependence supported by OAT (Capability), accessible and convenient healthcare like mobile outreach services coupled with financial incentives (Opportunity), and supportive relationships (Motivation) could serve to help people who inject drugs take up HCV treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Alcohol and other drug and primary care services for people who use drugs should adopt person-centred approaches and recognise the gradual nature of behavioural change to foster empathy and supportive relationships to promote engagement in HCV care. Additionally, integrating HCV treatment with mobile outreach services and providing practical assistance, such as housing and financial incentives, are critical to ensuring that individuals remain engaged in HCV care.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-024-01136-1","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T11:22:14Z","timestamp":1734693734000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Practical solutions to resolve social barriers to hepatitis C treatment initiation among people who inject drugs: a qualitative study"],"prefix":"10.1186","volume":"21","author":[{"given":"Phyo","family":"Aung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Hellard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Dietze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bek","family":"Petrovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Higgs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Stoov\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"1136_CR1","unstructured":"World Health Organization. Global Health Sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022\u20132030. Geneva; 2022."},{"issue":"2","key":"1136_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.18773\/austprescr.2021.003","volume":"44","author":"GJ Dore","year":"2021","unstructured":"Dore GJ. Elimination of hepatitis c in Australia by 2030: a decade and counting. Aust Prescr. 2021;44(2):36\u20137.","journal-title":"Aust Prescr"},{"key":"1136_CR3","unstructured":"Burnet Institute and Kirby Institute. Australia\u2019s progress towards hepatitis C elimination: Annual Report 2023. Melbourne; 2023."},{"key":"1136_CR4","doi-asserted-by":"publisher","unstructured":"Razavi H, Sanchez Gonzalez Y, Yuen C, Cornberg M. Global timing of hepatitis C virus elimination in high-income countries. Liver Int [Internet]. 2020;40(3):522\u20139. https:\/\/doi.org\/10.1111\/liv.14324","DOI":"10.1111\/liv.14324"},{"key":"1136_CR5","doi-asserted-by":"publisher","unstructured":"Kwon JA, Dore GJ, Hajarizadeh B, Alavi M, Valerio H, Grebely J et al. Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications. PLoS One [Internet]. 2021;16(9):e0257369. https:\/\/doi.org\/10.1371\/journal.pone.0257369","DOI":"10.1371\/journal.pone.0257369"},{"key":"1136_CR6","doi-asserted-by":"crossref","unstructured":"Alisa Pedrana S, Munari M, Stoove\u2019 J, Doyle MH. The phases of hepatitis C elimination: achieving WHO elimination targets. Melbourne; 2021.","DOI":"10.1016\/S2468-1253(20)30366-6"},{"key":"1136_CR7","doi-asserted-by":"crossref","unstructured":"Iversen J, Dore GJ, Starr M, Catlett B, Cunningham P, Geddes L et al. Estimating the Consensus Hepatitis C Cascade of Care among people who inject drugs in Australia: pre and post availability of direct acting antiviral therapy. Int J Drug Policy. 2020;83.","DOI":"10.1016\/j.drugpo.2020.102837"},{"key":"1136_CR8","doi-asserted-by":"publisher","unstructured":"Rockstroh JK, Boesecke C. Hepatitis C Virus Treatment as Prevention: Challenges and Opportunities in Men Who Have Sex With Men. J Infect Dis [Internet]. 2020;222(Supplement_9):S782\u20138. https:\/\/doi.org\/10.1093\/infdis\/jiaa096","DOI":"10.1093\/infdis\/jiaa096"},{"key":"1136_CR9","doi-asserted-by":"crossref","unstructured":"Hellard M, Schroeder SE, Pedrana A, Doyle J, Aitken C. The elimination of hepatitis C as a public health threat. Cold Spring Harb Perspect Med. 2020;10(4).","DOI":"10.1101\/cshperspect.a036939"},{"issue":"10","key":"1136_CR10","first-page":"958","volume":"26","author":"M Hellard","year":"2015","unstructured":"Hellard M, McBryde E, Davis RS, Rolls D, Higgs P, Aitken C, et al. Hepatitis C transmission and treatment as prevention \u2013 the role of the injecting network. IDJP. 2015;26(10):958\u201362.","journal-title":"IDJP"},{"key":"1136_CR11","doi-asserted-by":"publisher","first-page":"103706","DOI":"10.1016\/j.drugpo.2022.103706","volume":"105","author":"H Valerio","year":"2022","unstructured":"Valerio H, Alavi M, Conway A, Silk D, Treloar C, Martinello M, et al. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: the ETHOS Engage study. Int J Drug Policy. 2022;105:103706.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"1136_CR12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S2055-6640(20)30254-5","volume":"4","author":"JA Richmond","year":"2018","unstructured":"Richmond JA, Wallace J. Implementation of hepatitis C cure in Australia: one year on. J Virus Erad. 2018;4(2):115\u20137.","journal-title":"J Virus Erad"},{"key":"1136_CR13","doi-asserted-by":"publisher","unstructured":"H\u00f8j SB, Jacka B, Minoyan N, Artenie AA, Bruneau J. Conceptualising access in the direct-acting antiviral era: An integrated framework to inform research and practice in HCV care for people who inject drugs. Int J Drug Policy [Internet]. 2019;72:11\u201323. https:\/\/doi.org\/10.1016\/j.drugpo.2019.04.001","DOI":"10.1016\/j.drugpo.2019.04.001"},{"key":"1136_CR14","doi-asserted-by":"crossref","unstructured":"Heard E, Smirnov A, Massi L, Selvey LA. Personal, provider and system level barriers and enablers for hepatitis C treatment in the era of direct-acting antivirals: experiences of patients who inject drugs accessing treatment in general practice settings in Australia. J Subst Abuse Treat. 2021;127(November 2020).","DOI":"10.1016\/j.jsat.2021.108460"},{"issue":"1","key":"1136_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-019-1300-2","volume":"17","author":"HR Stagg","year":"2019","unstructured":"Stagg HR, Surey J, Francis M, MacLellan J, Foster GR, Charlett A, et al. Improving engagement with healthcare in hepatitis C: a randomised controlled trial of a peer support intervention. BMC Med. 2019;17(1):1\u20139.","journal-title":"BMC Med"},{"issue":"1","key":"1136_CR16","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1093\/cid\/ciaa571","volume":"73","author":"H Valerio","year":"2021","unstructured":"Valerio H, Alavi M, Silk D, Treloar C, Martinello M, Milat A, et al. Progress towards elimination of Hepatitis C infection among people who inject drugs in Australia: the ETHOS Engage Study. Clin Infect Dis. 2021;73(1):e69\u201378.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"1136_CR17","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/jvh.13112","volume":"26","author":"S Bajis","year":"2019","unstructured":"Bajis S, Grebely J, Cooper L, Smith J, Owen G, Chudleigh A, et al. Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: the LiveRLife homelessness study. J Viral Hepat. 2019;26(8):969\u201379.","journal-title":"J Viral Hepat"},{"key":"1136_CR18","doi-asserted-by":"publisher","unstructured":"Batchelder AW, Cockerham-Colas L, Peyser D, Reynoso SP, Soloway I, Litwin AH. Perceived benefits of the hepatitis C peer educators: a qualitative investigation. Harm Reduct J [Internet]. 2017;14(1):67. https:\/\/doi.org\/10.1186\/s12954-017-0192-8","DOI":"10.1186\/s12954-017-0192-8"},{"key":"1136_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.drugpo.2019.03.017","volume":"72","author":"ME Beiser","year":"2019","unstructured":"Beiser ME, Smith K, Ingemi M, Mulligan E, Baggett TP. Hepatitis C treatment outcomes among homeless-experienced individuals at a community health centre in Boston. Int J Drug Policy. 2019;72:129\u201337.","journal-title":"Int J Drug Policy"},{"key":"1136_CR20","doi-asserted-by":"crossref","unstructured":"Colledge S, Leung J, Larney S, Peacock A, Grebely J, Hickman M et al. Frequency of injecting among people who inject drugs: a systematic review and meta-analysis. Int J Drug Policy. 2020;76.","DOI":"10.1016\/j.drugpo.2019.102619"},{"issue":"1","key":"1136_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-018-0269-z","volume":"15","author":"D Crowley","year":"2018","unstructured":"Crowley D, Van Hout MC, Lambert JS, Kelly E, Murphy C, Cullen W. Barriers and facilitators to hepatitis C (HCV) screening and treatment - A description of prisoners\u2019 perspective. Harm Reduct J. 2018;15(1):1\u201310.","journal-title":"Harm Reduct J"},{"issue":"4","key":"1136_CR22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/SGA.0000000000000458","volume":"43","author":"JA Richmond","year":"2020","unstructured":"Richmond JA, Gallagher L, McDonald L, O\u2019Sullivan M, Fitzsimmons C, Pedrana A. Achieving Hepatitis C elimination by using Person-Centered, nurse-led models of care: a discussion of Four International Case studies. Gastroenterol Nurs. 2020;43(4):303\u20139.","journal-title":"Gastroenterol Nurs"},{"issue":"5","key":"1136_CR23","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/jvh.13259","volume":"27","author":"D Pourmarzi","year":"2020","unstructured":"Pourmarzi D, Smirnov A, Hall L, Thompson H, FitzGerald G, Rahman T. Enablers and barriers for the provision of community-based HCV treatment: a case study of a real-world practice. J Viral Hepat. 2020;27(5):484\u201396.","journal-title":"J Viral Hepat"},{"key":"1136_CR24","doi-asserted-by":"publisher","unstructured":"Papaluca T, McDonald L, Craigie A, Gibson A, Desmond P, Wong D et al. Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care. J Hepatol [Internet]. 2019;70(5):839\u201346. https:\/\/doi.org\/10.1016\/j.jhep.2019.01.012","DOI":"10.1016\/j.jhep.2019.01.012"},{"key":"1136_CR25","doi-asserted-by":"publisher","first-page":"103387","DOI":"10.1016\/j.drugpo.2021.103387","volume":"96","author":"J Gunn","year":"2021","unstructured":"Gunn J, McNally S, Ryan J, Layton C, Bryant M, Walker S, et al. Barriers to hepatitis C treatment among secondary needle and syringe program clients and opportunities to intervene. Int J Drug Policy. 2021;96:103387.","journal-title":"Int J Drug Policy"},{"key":"1136_CR26","doi-asserted-by":"publisher","unstructured":"Aung P, Goutzamanis S, Douglass C, Stoove M, Hellard M, Dietze P et al. Exploring opportunities for hepatitis C treatment uptake among people who inject drugs in Australia: a qualitative study. J Subst Use [Internet]. 2023;1\u20136. https:\/\/doi.org\/10.1080\/14659891.2023.2238317","DOI":"10.1080\/14659891.2023.2238317"},{"key":"1136_CR27","doi-asserted-by":"publisher","unstructured":"Crowley D, Cullen W, Lambert JS, Van Hout MC. Competing priorities and second chances - A qualitative exploration of prisoners\u2019 journeys through the Hepatitis C continuum of care. PLoS One [Internet]. 2019;14(9):e0222186. https:\/\/doi.org\/10.1371\/journal.pone.0222186","DOI":"10.1371\/journal.pone.0222186"},{"key":"1136_CR28","doi-asserted-by":"publisher","unstructured":"McColl R, Higgs P, Harney B. No, my name\u2019s not on the lease at all: an interpretive phenomenological analysis of unstable housing and hepatitis C among people who inject drugs. Drugs, Habits Soc Policy [Internet]. 2024;ahead-of-p(ahead-of-print). https:\/\/doi.org\/10.1108\/DHS-08-2023-0034","DOI":"10.1108\/DHS-08-2023-0034"},{"issue":"1","key":"1136_CR29","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1186\/s13063-024-08212-8","volume":"25","author":"P Fathima","year":"2024","unstructured":"Fathima P, Jones M, D\u2019Souza R, Totterdell J, Andric N, Abbott P, et al. Financial incentives to motivate treatment for hepatitis C with direct acting antivirals among Australian adults (the methodical evaluation and optimisation of targeted IncentiVes for accessing treatment of early-stage hepatitis C: MOTIVATE-C): protocol. Trials. 2024;25(1):387.","journal-title":"Trials"},{"issue":"9","key":"1136_CR30","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.sapharm.2019.04.004","volume":"16","author":"J Gunn","year":"2020","unstructured":"Gunn J, Higgs P. Directly observed hepatitis C treatment with opioid substitution therapy in community pharmacies: a qualitative study. Res Social Adm Pharm. 2020;16(9):1298\u2013301.","journal-title":"Res Social Adm Pharm"},{"key":"1136_CR31","doi-asserted-by":"publisher","first-page":"108464","DOI":"10.1016\/j.drugalcdep.2020.108464","volume":"219","author":"NR Jones","year":"2021","unstructured":"Jones NR, Nielsen S, Farrell M, Ali R, Gill A, Larney S, et al. Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001\u20132018: implications for treatment systems and potential impact on client outcomes. Drug Alcohol Depend. 2021;219:108464.","journal-title":"Drug Alcohol Depend"},{"key":"1136_CR32","doi-asserted-by":"crossref","unstructured":"Goutzamanis S, Doyle JS, Horyniak D, Higgs P, Hellard M. Peer to peer communication about hepatitis C treatment amongst people who inject drugs: a longitudinal qualitative study. Int J Drug Policy. 2021;87.","DOI":"10.1016\/j.drugpo.2020.102983"},{"key":"1136_CR33","doi-asserted-by":"publisher","unstructured":"Michie S, van Stralen MM, West R. The behaviour change wheel: A new method for characterising and designing behaviour change interventions. Implement Sci [Internet]. 2011;6(1):42. https:\/\/doi.org\/10.1186\/1748-5908-6-42","DOI":"10.1186\/1748-5908-6-42"},{"key":"1136_CR34","doi-asserted-by":"publisher","unstructured":"Van Den Boom W, Quiroga M, del O\u2019Keefe M, Kumar D, Hill D, Scott PL et al. N,. Cohort Profile: The Melbourne Injecting Drug User Cohort Study (SuperMIX). Int J Epidemiol [Internet]. 2021;dyab231. https:\/\/doi.org\/10.1093\/ije\/dyab231","DOI":"10.1093\/ije\/dyab231"},{"key":"1136_CR35","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.drugalcdep.2018.06.013","volume":"190","author":"MR Skeer","year":"2018","unstructured":"Skeer MR, Ladin K, Wilkins LE, Landy DM, Stopka TJ. Hep C\u2019s like the common cold: understanding barriers along the HCV care continuum among young people who inject drugs. Drug Alcohol Depend. 2018;190:246\u201354.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1136_CR36","first-page":"48","volume":"25","author":"M Paisi","year":"2022","unstructured":"Paisi M, Crombag N, Burns L, Bogaerts A, Withers L, Bates L, et al. Barriers and facilitators to hepatitis C screening and treatment for people with lived experience of homelessness: a mixed-methods systematic review. Heal Expect Int J Public Particip Heal care Heal Policy. 2022;25(1):48\u201360.","journal-title":"Heal Expect Int J Public Particip Heal care Heal Policy"},{"key":"1136_CR37","doi-asserted-by":"publisher","first-page":"103261","DOI":"10.1016\/j.drugpo.2021.103261","volume":"95","author":"C Treloar","year":"2021","unstructured":"Treloar C, Schroeder S, Lafferty L, Marshall A, Drysdale K, Higgs P, et al. Structural competency in the post-prison period for people who inject drugs: a qualitative case study. Int J Drug Policy. 2021;95:103261.","journal-title":"Int J Drug Policy"},{"key":"1136_CR38","doi-asserted-by":"crossref","unstructured":"Barnett A, Savic M, Lintzeris N, Bathish R, Arunogiri S, Dunlop AJ et al. Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients\u2019 experiences in Australia. Drug Alcohol Depend [Internet]. 2021;227:108959. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0376871621004543","DOI":"10.1016\/j.drugalcdep.2021.108959"},{"key":"1136_CR39","doi-asserted-by":"publisher","unstructured":"Byrne CJ, Radley A, Inglis SK, Beer L, Palmer N, Duc Pham M et al. Reaching people receiving opioid agonist therapy at community pharmacies with hepatitis C virus: an international randomised controlled trial. Aliment Pharmacol Ther [Internet]. 2022;55(12):1512\u201323. https:\/\/doi.org\/10.1111\/apt.16953","DOI":"10.1111\/apt.16953"},{"issue":"9","key":"1136_CR40","doi-asserted-by":"publisher","first-page":"543","DOI":"10.5498\/wjp.v11.i9.543","volume":"11","author":"M Soyka","year":"2021","unstructured":"Soyka M, Franke AG. Recent advances in the treatment of opioid use disorders-focus on long-acting buprenorphine formulations. World J Psychiatry. 2021;11(9):543\u201352.","journal-title":"World J Psychiatry"},{"key":"1136_CR41","unstructured":"University of Sydney. The MotivateC Project [Internet]. 2024 [cited 2024 Jun 13]. https:\/\/motivatec-project.sydney.edu.au\/about\/"},{"key":"1136_CR42","doi-asserted-by":"publisher","unstructured":"Wohl DA, Allmon AG, Evon D, Hurt C, Reifeis SA, Thirumurthy H et al. Financial Incentives for Adherence to Hepatitis C Virus Clinical Care and Treatment: A Randomized Trial of Two Strategies. Open Forum Infect Dis [Internet]. 2017;4(2):ofx095. https:\/\/doi.org\/10.1093\/ofid\/ofx095","DOI":"10.1093\/ofid\/ofx095"},{"issue":"1","key":"1136_CR43","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/S2468-1253(20)30366-6","volume":"6","author":"A Pedrana","year":"2021","unstructured":"Pedrana A, Munari S, Stoove M, Doyle JHM. Comment the phases of hepatitis C elimination: achieving WHO elimination targets. Lancet Gastroenterol Hepatol. 2021;6(1):6\u20138.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1136_CR44","doi-asserted-by":"publisher","unstructured":"Palmer AY, Chan K, Gold J, Layton C, Elsum I, Hellard M et al. A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign. J Viral Hepat [Internet]. 2021;28(11):1624\u201334. https:\/\/doi.org\/10.1111\/jvh.13596","DOI":"10.1111\/jvh.13596"},{"key":"1136_CR45","doi-asserted-by":"publisher","unstructured":"Conway B, Sharma S, Yung R, Yi S, Toniato G. Current Models to Address Obstacles to HCV Elimination. In: Yang L, Qi X, editors. Rijeka: IntechOpen; 2023. p. Ch. 5. https:\/\/doi.org\/10.5772\/intechopen.1001867","DOI":"10.5772\/intechopen.1001867"},{"issue":"2","key":"1136_CR46","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.drugalcdep.2013.07.023","volume":"133","author":"C Treloar","year":"2013","unstructured":"Treloar C, Rance J, Grebely J, Dore GJ. Client and staff experiences of a co-located service for hepatitis C care in opioid substitution treatment settings in New South Wales, Australia. Drug Alcohol Depend. 2013;133(2):529\u201334.","journal-title":"Drug Alcohol Depend"},{"key":"1136_CR47","doi-asserted-by":"crossref","unstructured":"Dawe J, Wilkinson AL, Asselin J, Carter A, Pedrana A, Traeger MW et al. Hepatitis C antibody testing among opioid agonist therapy recipients, Victoria, Australia, 2012 to 2020. Int J Drug Policy [Internet]. 2022;104:103696. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0955395922001153","DOI":"10.1016\/j.drugpo.2022.103696"},{"issue":"6","key":"1136_CR48","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.3122\/jabfm.2021.06.210137","volume":"34","author":"R Marx","year":"2021","unstructured":"Marx R, Kahn JG. A narrative review of slow Medicine outcomes. J Am Board Fam Med. 2021;34(6):1249\u201364.","journal-title":"J Am Board Fam Med"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01136-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-01136-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01136-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T12:04:42Z","timestamp":1734696282000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-01136-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1136"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-01136-1","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]},"assertion":[{"value":"13 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Alfred Health Ethics Committee (#612\/23).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. Data were de-identified and only pseudonyms were used in the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"221"}}